MicroPort® EP Obtains Approval for OptimAblate™ Cardiac RF Generator from National Medical Products Administration of China (NMPA)

Shanghai, China –Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP”) recently obtained the registration certificate for its independently developed OptimAblate™ Cardiac RF Generator from National Medical Products Administration of China (NMPA).

 

The OptimAblate™ Cardiac RF Generator is used to provide radiofrequency energy for catheter radiofrequency ablation in the treatment of tachyarrhythmia. The high-frequency energy heats tissues to block or damage abnormal pathway and restore sinus rhythm. The OptimAblate™ Cardiac RF Generator applies a tilted wide-angle screen and a high-definition touchscreen with a friendly and intuitive interface. When it communicates with Columbus® 3D EP Navigation System (“Columbus®”), the OptimAblate™ Cardiac RF Generator can display capacity, temperature, impedance and ablation time on the same multi-channel screen during the operations, which increases convenience for the doctors to operate the devices. When the irrigated ablation catheter is selected, the OptimAblate™ Cardiac RF Generator can interact with OptimAblate™ Irrigation Pump to display and operate high and low irrigation velocity, and to provide multiple personalized settings and storage of ablation parameters.

 

Previously, OptimAblate™ Cardiac RF Generator had obtained approvals for launch in the overseas markets after receiving the CE mark in Europe. The NMPA approval is significant in that one more device-category product of MicroPort® EP will officially enter the Chinese market following Columbus® and OptimAblate™ Irrigation Pump. It also marks that MicroPort® EP has made strides once again to become a provider of a complete electrophysiological solution platform that combines active devices with passive devices and devices with equipment.